Immix Biopharma (IMMX) Current Assets (2020 - 2026)

Immix Biopharma has disclosed Current Assets across 7 years of filings, most recently posting $92.3 million for Q1 2026.

• Current Assets for Q1 2026 came in at $92.3 million, up 449.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.3 million (up 449.93% YoY), and the FY2025 annual result was $101.2 million, up 401.23% from the prior year.
• Current Assets came in at $92.3 million for Q1 2026 at Immix Biopharma, down from $101.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $101.2 million in Q4 2025 to a low of $12.3 million in Q2 2025.
• The 5-year median for Current Assets is $19.8 million (2023), against an average of $28.5 million.
• Across the five-year window, Current Assets tumbled 54.9% in 2025 and jumped 449.93% in 2026, its largest moves.
• Immix Biopharma's Current Assets stood at $14.9 million in 2022, then jumped by 32.82% to $19.8 million in 2023, then climbed by 2.07% to $20.2 million in 2024, then soared by 401.23% to $101.2 million in 2025, then retreated by 8.85% to $92.3 million in 2026.
• The last three Current Assets figures came in at $92.3 million (Q1 2026), $101.2 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.